PHARMACY ACCOUNT & ACCESS ACT
HB3670 creates the Pharmacy Accountability and Access Act, a new Illinois law aimed at regulating the closure of pharmacies, especially larger corporate operators. The bill requires covered pharmacy owners—those with more than 10 locations statewide or at least $50 million in annual gross revenue—to give 180 days’ written notice before closing a pharmacy, post that notice at the site and on the company website, and notify state and local officials and interested community leaders. It also requires a closure justification report describing the reasons for the shutdown, including financial losses, operational inefficiencies, and how the decision fits the company’s social responsibility commitments.
The bill further requires at least two public meetings during the notice period, with in-person and virtual participation options, and mandates a community transition plan addressing continued access to prescriptions and health care services. The Department of Public Health must review transition plans, assess impacts on access and outcomes, and specifically review closures in medically underserved communities. The bill also authorizes repayment of tax incentives, subsidies, or other public financial benefits if the company fails to comply, and imposes penalties for noncompliance.
HB3670 would add a new regulatory framework to Illinois law governing pharmacy closures, supplementing the Pharmacy Practice Act and creating new duties for pharmacy owners, the Department of Financial and Professional Regulation, and the Department of Public Health. It would impose advance notice, reporting, public meeting, and transition-planning requirements on larger pharmacy operators, while also creating potential financial consequences tied to public incentives and subsidies. The bill would especially affect chain pharmacies and corporate pharmacy owners, and it would give state and local government a more active role in reviewing closures that could reduce access to medications and health care services.
Based on the bill text and the absence of recorded committee testimony or votes in the provided materials, the overall sentiment appears supportive of pharmacy access and community transparency rather than adversarial. The measure is framed as a consumer- and community-protection bill, with emphasis on preventing abrupt closures and ensuring continuity of care. Because no committee discussion or vote history is included, there is no documented public opposition or endorsement to gauge beyond the bill’s stated policy goals.
The main points of contention likely concern the burden the bill places on pharmacy operators, particularly large chains, by requiring lengthy notice, detailed financial disclosures, public meetings, and transition planning before closure. Another likely issue is the repayment provision, which could require companies to return tax incentives or subsidies if they do not comply, creating a significant financial penalty. Supporters would likely emphasize access to medications, transparency, and protection for medically underserved communities, while critics may argue the bill could limit business flexibility or discourage investment in pharmacy locations.